CENIX BIOSCIENCE Announces Collaboration with Bayer HealthCare AG to Discover and Validate Novel Therapeutic Targets

06-Jan-2004

Dresden, Germany, - Cenix BioScience GmbH (Dresden) today announced a research collaboration with Bayer HealthCare AG (Leverkusen) to rapidly screen through all known human druggable genes using RNA interference (RNAi) to identify and validate new therapeutic drug targets for several disease indications. Using cell-based assays co-developed with Bayer research teams in Wuppertal (Germany) and West Haven (USA), Cenix will apply its proprietary genome-based high throughput (HT) RNAi screening platform over 6,000 genes in less than 9 months.

"Having launched these HT-RNAi research offerings only this summer after years of careful R&D, we have been particularly gratified by the overwhelming market interest, of which this agreement represents a first, important milestone" said Dr Echeverri, CEO and CSO of Cenix BioScience GmbH.

The project will make use of the genome-wide library of siRNA molecules designed by Cenix using its industry-leading algorithms and produced by Ambion, Inc. (Austin, TX, USA). Under the deal, Cenix will receive upfront payments and research funding, and is eligible for downstream milestone payments. Bayer will have the option to obtain all rights to new intellectual property generated by the project.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances